ANTIBODIES TO OLANZAPINE AND USE THEREOF
First Claim
Patent Images
1. An isolated antibody or a binding fragment thereof, which binds to olanzapine, comprising:
- a) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
11 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
12;
b) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
15 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
16;
c) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
31 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
32;
d) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
35 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
36;
ore) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
39 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
40, andwherein the antibody comprises the CDR1, CDR2, and CDR3 regions of the light chain variable region and the CDR1, CDR2, and CDR3 regions of the heavy chain variable region.
3 Assignments
0 Petitions
Accused Products
Abstract
Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
-
Citations
25 Claims
-
1. An isolated antibody or a binding fragment thereof, which binds to olanzapine, comprising:
-
a) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
11 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
12;b) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
15 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
16;c) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
31 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
32;d) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
35 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
36;
ore) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
39 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;
40, andwherein the antibody comprises the CDR1, CDR2, and CDR3 regions of the light chain variable region and the CDR1, CDR2, and CDR3 regions of the heavy chain variable region. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
-
Specification